Study Name:
Study of BDTX-1535, in Participants With Glioblastoma or Non-Small Cell Lung Cancer
Targeted Disease(s):
Lung Cancer
Purpose of Study:
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of BDTX-1535 in patients with GBM or NSCLC harboring sensitive EGFR alterations and who have disease progression following standard of care
Study Dates:
March 31, 2022 - September 30, 2024
Study Location:
Nationwide
Funding Source:
Black Diamond Therapeutics, Inc.
Sponsors:
Black Diamond Therapeutics, Inc.
Contact:
BDTX Clinical Team
ContactPhone: 617- 252-0848
ContactEmail: [email protected]
ClinicalTrails.gov Identifier:
NCT05256290
Contact:
BDTX Clinical Team
ContactPhone: 617- 252-0848
ContactEmail: [email protected]
